Raised troponin in COPD: Clinical implications and possible mechanisms

Heart

Volumn 99, Issue 2, 2013, Pages 71-72

  Stone, IanS ^a   Petersen, Steffen E ^a   Barnes, Neil C ^a  

^a LONDON CHEST HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; TROPONIN;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CORONARY ARTERY DISEASE; DISEASE EXACERBATION; EDITORIAL; HEART AFTERLOAD; HEART LEFT VENTRICLE HYPERTROPHY; HEART MUSCLE INJURY; HEART PROTECTION; HEART RIGHT VENTRICLE FAILURE; HUMAN; HYPERINFLATION; HYPOXIA; INFLAMMATION; PRIORITY JOURNAL; PULMONARY REHABILITATION; PULSE WAVE; TACHYCARDIA;

EID: 85027926517     PISSN: 13556037     EISSN: 1468201X     Source Type: Journal    
DOI: 10.1136/heartjnl-2012-302969     Document Type: Editorial

References (16)

1. Stone IS, Barnes NC, Petersen SE. Chronic obstructive pulmonary disease: a modifiable risk factor for cardiovascular disease? Heart 2012;98:1055-62.
2. Baillard C, Boussarsar M, Fosse JP, et al. Cardiac troponin I in patients with severe exacerbation of chronic obstructive pulmonary disease. Intensive Care Med 2003;29:584-9. (Pubitemid 36523675)
3. Chang CL, Robinson SC, Mills GD, et al. Biochemical markers of cardiac dysfunction predict mortality in acute exacerbations of COPD. Thorax 2011;66:764-8.
4. Marcun R, Sustic A, Brguljan PM, et al. Cardiac biomarkers predict outcome after hospitalisation for an acute exacerbation of chronic obstructive pulmonary disease. Int J Cardiol 2012;161:156-9.
5. Soyseth V, Bhatnagar R, Holmedahl NH, et al. Acute exacerbation of COPD is associated with fourfold elevation of cardiac troponin T. Heart 2013;99:122-6.
6. Rutten FH, Zuithoff NP, Hak E, et al. Beta-blockers may reduce mortality and risk of exacerbations in patients with chronic obstructive pulmonary disease. Arch Intern Med 2010;170:880-7.
7. Soyseth V, Brekke PH, Smith P, et al. Statin use is associated with reduced mortality in COPD. Eur Respir J 2007;29:279-83. (Pubitemid 46237383)
8. Mahajan N, Mehta Y, Rose M, et al. Elevated troponin level is not synonymous with myocardial infarction. Int J Cardiol 2006;111:442-9. (Pubitemid 44205299)
9. Agusti A, Edwards LD, Rennard SI, et al. Persistent systemic inflammation is associated with poor clinical outcomes in COPD: a novel phenotype. PLoS One 2012;7:e37483.
10. Maclay JD, McAllister DA, Johnston S, et al. Increased platelet activation in patients with stable and acute exacerbation of COPD. Thorax 2011;66:769-74.
11. Schillaci G, Battista F, Pucci G. A review of the role of electrocardiography in the diagnosis of left ventricular hypertrophy in hypertension. J Electrocardiol 2012;45:617-23.
12. Ikonomidis I, Lekakis J, Papadopoulos C, et al. Incremental value of pulse wave velocity in the determination of coronary microcirculatory dysfunction in never-treated patients with essential hypertension. Am J Hypertens 2008;21:806-13. (Pubitemid 351913610)
13. Sabit R, Bolton CE, Edwards PH, et al. Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2007;175:1259-65. (Pubitemid 46905751)
14. Patel ARC, Kowlessar BS, Mackay AC, et al. The Time-course Of Changes In Arterial Stiffness During COPD Excacerbations. Abstract A5853 American Thorcaic Society Conference; San Francisco, 2012.
15. Gale NS, Duckers JM, Enright S, et al. Does pulmonary rehabilitation address cardiovascular risk factors in patients with COPD? BMC Pulm Med 2011;11:20.
16. Dransfield MT, Cockcroft JR, Townsend RR, et al. Effect of fluticasone propionate/salmeterol on arterial stiffness in patients with COPD. Respir Med 2011;105:1322-30.